Semaglutide has been demonstrated to trigger medullary thyroid mobile carcinoma in rodents. While its scientific relevance to humans is unfamiliar, the FDA advises not to administer this drug in those with a personal or loved ones record of medullary thyroid carcinoma. Semaglutide also poses a threat of pancreatitis and dehydration. https://peptides99801.blogzet.com/indicators-on-peptides-you-should-know-45423487